Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director

Rhea-AI Filing Summary

KAZIA THERAPEUTICS LTD reported a compensation-related equity grant to executive David Cain, Director, CMC. He received 100,000 employee stock options over ADSs, with an exercise price of $9.10 per ADS and no cash consideration for the grant. One-third of the options vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches on each anniversary of that date. The options expire on January 8, 2029, creating a multi-year incentive tied to the company’s share performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cain David

Role Director, CMC

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	100,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 100,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 100,000 options Exercise price: $9.10 per ADS Vesting commencement: January 8, 2027 +4 more

7 metrics

Option grant size 100,000 options Employee stock option award over ADSs to David Cain

Exercise price $9.10 per ADS Strike price for the granted employee stock options

Vesting commencement January 8, 2027 One-third of options vest on this date

Full vesting schedule Remaining two-thirds yearly Vest in equal yearly tranches on anniversary of January 8, 2027

Expiration date January 8, 2029 Date on which unexercised options lapse

Shares underlying options 100,000 ADSs Underlying security covered by this option grant

Post-grant derivative holdings 100,000 options Total options held following this reported transaction

Key Terms

Employee Stock Option (right to buy), ADSs, Remuneration Committee, employee share plan

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

ADSs financial

"underlying_security_title: ADSs"

Remuneration Committee financial

"approved by the Remuneration Committee on January 8, 2026"

A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.

employee share plan financial

"grants under the Issuer's employee share plan"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/08/2026 - 04:58 PM Accepted by SEC EDGAR 07/08/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cain David

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS, LEVEL 24

300 BARANGAROO AVENUE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Director, CMC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$9.1	01/08/2026		A		100,000(1)		(1)	(1)	ADSs	100,000	$0	100,000	D

Explanation of Responses:

1. Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

	/s/ Jeffrey Bonacorda - Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)